A coronavirus vaccine from Germany’s BioNTech has yielded positive trial results, generating immune defences in participants that were stronger than those of the average recovered Covid-19 patient, according to preliminary data released by the company.
据德国制药公司BioNTech发布的初步数据，该公司的一种新型冠状病毒疫苗在试验中取得了积极的结果，受试者所产生的免疫防御能力要强于新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）康复患者的平均抗体水平。
您已阅读6%（359字），剩余94%（5978字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。